Cargando…

Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study

PURPOSE: To compare monthly versus pro re nata (PRN) ranibizumab injections in the treatment of exudative macular degeneration (AMD) while assessing the utility of microperimetry (MP) and multifocal electroretinography (mfERG) testing when monitoring response to treatment. METHODS: A randomized expl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asahi, Masumi G, Wallsh, Josh, Onishi, Spencer M, Kuroyama, Shari, Gallemore, Ron P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605973/ https://www.ncbi.nlm.nih.gov/pubmed/33154619 http://dx.doi.org/10.2147/OPTH.S270243

Ejemplares similares

Long-Term Outcomes of Macular Hole Repair with Triamcinolone Acetonide Visualization
por: Wallsh, Josh, et al.
Publicado: (2021)

Outcomes of Epiretinal Membrane Removal Utilizing Triamcinolone Acetonide Visualization and Internal Limiting Membrane Forceps
por: Asahi, Masumi G, et al.
Publicado: (2020)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
por: Gallemore, Ron P, et al.
Publicado: (2017)

Identifying rhegmatogenous detachments in bullous retinoschisis with optical coherence tomography studies
por: Wallsh, Josh O, et al.
Publicado: (2016)

Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy
por: Wallsh, Josh, et al.
Publicado: (2016)

Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options
por: Wallsh, Josh O., et al.
Publicado: (2021)

Topical difluprednate for the treatment of Harada’s disease
por: Onishi, Spencer M, et al.
Publicado: (2015)

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
por: Waizel, Maria, et al.
Publicado: (2017)

Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review
por: Wallsh, Josh, et al.
Publicado: (2020)

Strong topical steroid, NSAID, and carbonic anhydrase inhibitor cocktail for treatment of cystoid macular edema
por: Asahi, Masumi G, et al.
Publicado: (2015)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial
por: Russo, Andrea, et al.
Publicado: (2018)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Photodynamic therapy combined with antivascular endothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy
por: Asahi, Masumi G, et al.
Publicado: (2017)

Comparison of Fundus-Guided Microperimetry and Multifocal Electroretinography for Evaluating Hydroxychloroquine Maculopathy
por: Alghanem, Husam, et al.
Publicado: (2019)

Acute macular edema following intracorporeal prostaglandin injection for erectile dysfunction
por: Asahi, Masumi G, et al.
Publicado: (2015)

Improving treatment provision of Wet AMD with intravitreal ranibizumab
por: Ghazala, Fadi, et al.
Publicado: (2013)

Visual Snow-Like Symptoms and Posterior Uveitis following COVID-19 Infection
por: Braceros, Kathryn Kelani, et al.
Publicado: (2021)

The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes
por: Butt, Thomas, et al.
Publicado: (2015)

Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
por: Lotery, A, et al.
Publicado: (2017)

A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
por: Johnston, Robert L., et al.
Publicado: (2017)

Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up
por: Matsumiya, Wataru, et al.
Publicado: (2013)

Testing the clinical value of multifocal electroretinography and microperimetry and the effects of intravitreal therapy with ranibizumab on macular function in the course of wet age-related macular degeneration: a 1-year prospective study
por: Reinsberg, Mihaela, et al.
Publicado: (2017)

Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme
por: Holz, Frank G, et al.
Publicado: (2013)

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
por: Tran, Thi Ha Chau, et al.
Publicado: (2017)

Findings of uncertain significance by optical coherence tomography (OCT) as prognostic factors in neovascular age-related macular degeneration (nAMD) treated with ranibizumab
por: Hayashi-Mercado, Ricardo, et al.
Publicado: (2022)

Mechanisms of FH Protection Against Neovascular AMD
por: Borras, Céline, et al.
Publicado: (2020)

The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD
por: Viggiano, Pasquale, et al.
Publicado: (2023)

Ranibizumab for the treatment of wet AMD: a summary of real-world studies
por: Chong, V
Publicado: (2016)

Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
por: Abou-Ltaif, Sleiman
Publicado: (2016)

Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
por: Tran, Thi Ha Chau, et al.
Publicado: (2018)

Aqueous Fluid Transcriptome Profiling Differentiates Between Non-Neovascular and Neovascular AMD
por: Kaidonis, Georgia, et al.
Publicado: (2023)

Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
por: Otsuji, Tsuyoshi, et al.
Publicado: (2013)

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
por: Chen, Eric R, et al.
Publicado: (2020)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
por: Luksa, Dorota, et al.
Publicado: (2021)

Regulation of signaling events involved in the pathophysiology of neovascular AMD
por: Wang, Haibo, et al.
Publicado: (2016)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

Gains in the current understanding of managing neovascular AMD with brolucizumab
por: Bodaghi, Bahram, et al.
Publicado: (2023)

Single intravitreal ranibizumab for myopic choroidal neovascularization
por: Nor-Masniwati, Saidin, et al.
Publicado: (2011)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_58mj2ghkm3807egv3gut8m7cdt